Business
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
(TheNewswire) Toronto, Ontario – TheNewswire - 15 December, 2025 – He...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Toronto, Ontario –\n \n\n TheNewswire\n-\n \n\n 15 December, 2025 – Helix BioPharma Corp.\n(TSX:\n \n\n “HBP”\n \n\n , OTC PINK:\n \n\n “HBPCD”\n \n\n , FRANKFURT:\n \n\n “HBP0”\n \n\n )\n(\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology\ncompany shaping a near future where today’s hard-to-treat cancers\nare vincible,\n \n\n announces the filing of the\nCompany’s unaudited interim financial statements as of and for the\nthree month period ended October 31, 2025 (the\n \n\n “Financial Statements”\n \n\n ), the management’s discussion and analysis (\n \n\n “MD&A”\n \n\n ), and\nthe certifications of the Chief Executive Officer and Chief Financial\nOfficer (respectively,\n \n\n “CEO”\n \n\n and\n \n\n “CFO”\n \n\n ) relating\nto the Financial Statements (collectively, the\n \n\n “Interim Filings”\n \n\n ). The Interim Filings are available on the Company’s\nprofile at\n \n\n\n\n www.sedarplus.ca\n \n\n\n\n and on its website\nat\n \n\n\n\n https://www.helixbiopharma.com/filings-and-financials/\n \n\n\n\n .\n \n\n\n\n About Helix BioPharma\n \n\n\n\n Helix BioPharma is an oncology company that innovates\nfrom strength to bring near-term solutions for today’s\nhardest-to-treat cancers. The Company’s pipeline is led by Tumor\nDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate\ndesigned to prime CEACAM6-expressing tumors for increased sensitivity\nto therapy and augment the effectiveness of today’s front-running\nanti-cancer treatments. L-DOS47 has completed Phase Ib studies in\nnon-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting\nfoundation with Helix’s next-generation bi-specific antibody-drug\nconjugates (ADCs), currently in discovery. The Company also advances\ntwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint\nmodulator aimed at achieving durable remission in post-transplant\nleukemia relapse, and (ii) GEMCEDA™, a first-in-class oral\nge...